In the preliminary study, as compared with the control (0 mM), significantly increased fungicidal activity was observed with increasing concentration of Histatin-5 (Fig. 1) . Thus in the further analysis, the fungicidal activity of Histatin-5 at the final concentration of 50 mM was employed. At this concentration, Histatin-5 killed more than 95% of C. albicans A6, A8
Purpose. Fungicidal effects of Histatin-5 against oral isolates of Candida albicans from HIVpositive and -negative patients were examined. Methods/Materials.
Two isolates of C. albicans from HIV-positive patients (two males), three isolates from HIV-negative patients (two males amd one female healthy donors) and one ATCC strain were used. Fungicidal assays were performed on exponential C. albicans cells in the presence or absence of Histatin-5 (0.315-50 mM). Results. Fifty mM Histatin-5 killed more than 95% of C. albicans isolates from HIV-negative patients and killed more than 90% of ATCC strain. In contrast, Histatin-5 induced 75.3% and 66.1% loss of viability of two C. albicans isolates from HIV-positive patients, respectively, which were statistically less effective than the fungicidal effects against any isolates from HIV negative patients, or a reference strain (ANOVA; p<0.05). Conclusion. C. albicans isolates from oral cavity of HIV-positive patients were less sensitive In the preliminary study, as compared with the control (0 mM), significantly increased fungicidal activity was observed with increasing concentration of Histatin-5 (Fig. 1) . Thus in the further analysis, the fungicidal activity of Histatin-5 at the final concentration of 50 mM was employed. At this concentration, Histatin-5 killed more than 95% of C. albicans A6, A8
and A10 and killed more than 90% of ATCC strain (Fig. 2) . In contrast, Histatin-5 induced 75.3% and 66.1% loss of viability of the C. albicans Al and A2 cells, respectively (Fig. 2) .
Thus, C. albicans Al was statistically less susceptible than any of oral isolates from HIV negative patients (Tables 1 and 2 ; p<0.05), while there was no significant differences between the sensitibity of C. albicans Al and ATCC strain (Tables 1 and 2 ; p>0.05), which was used as a reference strain. In contrast, C. albicans A2 was statistically less sensitive than either isolates from HIV negative patients, and or a reference strain (Tables 1 and 2 ; p<0.05).
DISCUSSION
The family of salivary histatins consists of structurally related, low molecular weight histidine rich proteins, which are part of the non-immune host defense system of the oral- and that killed more than 90% of ATCC strain, which was used as reference strain, were consistent with the results of previous studies. However, the same concentration of the peptide (which killed more than 95% of C. albicans isolates from HIV negative patients), induced only 75.3% and 66.1% loss of viability of the C. albicans Al and A2 cells, isolated from oral cavity of HIV positive patients, respectively. The finding implies that the C. albicans isolates exsist in AIDS patients should be less susceptible to Histatin-5 in saliva, as compared with the isolates from HIV-negative patients. It has been considered that the decrease in histatin concentration in the saliva of AIDS patients18 may partially explain why more than 70% of AIDS patients develop oral candidiasis over the course of the disease20. In addition to this, there is a possibility that the changes in susceptibility of C. albicans isolates to Histatin-5 may be attributed to the latter phenomena. Although our results, from the limited number of C. albicans isolates, taken together, supported the therapeuic potentials of Histatin-5 for oral candidosis as previously suggested, we raised here the possible problem of application of Histatin-5 to the control of oral Candida isolates for HIV-positive patients. Further trials to improve the fungicidal potential of basic peptides should be required.
CONCLUSIONS
In the present study, we examined the fungicidal potential of Histatin-5 against totally 6 isolates of C. albicans (2 isolates from oral cavities of HIV positive patients, 3 isolates from oral cavity of HIV negative patients, and one from ATCC). 
